News
Amgen’s KRAS inhibitor Lumakras scores positive overall survival data
Amgen has presented new data on overall survival (OS) for its KRAS inhibitor Lumakras in previously treated non-small cell lung cancer (NSCLC) at the 2021 American Society of Clinical Oncology (ASCO) annual meeting.